간행물

대한간암학회> 대한간암학회지

대한간암학회지 update

Journal of liver cancer

  • : 대한간암학회
  • : 의약학분야  >  내과학
  • : KCI등재
  • :
  • : 연속간행물
  • : 반년간
  • : 2288-8128
  • : 2283-5001
  • : 대한간암연구회지(~2010)→대한간암연구학회지(2011~)

수록정보
수록범위 : 1권0호(2001)~22권1호(2022) |수록논문 수 : 540
대한간암학회지
22권1호(2022년 03월) 수록논문
최근 권호 논문
| | | |

KCI등재

1Is multidisciplinary treatment effective for hepatocellular carcinoma with portal vein tumor thrombus?

저자 : Won Hyeok Choe

발행기관 : 대한간암학회 간행물 : 대한간암학회지 22권 1호 발행 연도 : 2022 페이지 : pp. 1-3 (3 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

KCI등재

2Radioembolization for hepatocellular carcinoma: what clinicians need to know

저자 : Jin Woo Choi , Hyo-cheol Kim

발행기관 : 대한간암학회 간행물 : 대한간암학회지 22권 1호 발행 연도 : 2022 페이지 : pp. 4-13 (10 pages)

다운로드

(기관인증 필요)

초록보기

Transarterial radioembolization (TARE) with yttrium 90 (90Y) has been used in the management of hepatocellular carcinoma (HCC) for more than 10 years in Korea. There are two types of 90Y radioactive microspheres available, namely, glass and resin microspheres, with comparable clinical outcomes. In general, TARE outperforms transarterial chemoembolization regarding post-embolization syndrome, time to progression, tumor downsizing for liver transplantation, and hospitalization stay. Although TARE is commonly recommended for patients with unresectable large HCCs, it can be an alternative to or performed in combination with ablation, surgical resection, and systemic treatment. This review aimed to address 90Y radioactive microspheres, patient selection, clinical outcomes, simulation tests, radioembolization procedures, follow-up imaging, and complications. (J Liver Cancer 2022;22:4-13)

KCI등재

3A clinical and pathological update on hepatocellular carcinoma

저자 : Salvatore Lorenzo Renne , Luca Di Tommaso

발행기관 : 대한간암학회 간행물 : 대한간암학회지 22권 1호 발행 연도 : 2022 페이지 : pp. 14-22 (9 pages)

다운로드

(기관인증 필요)

초록보기

It is estimated that more than 1 million individuals will be affected annually by hepatocellular carcinoma (HCC) by 2025. HCC can be broadly grouped into two major molecular subgroups, each of which is characterized by specific morphological and phenotypic features that mirror the genetic background. The use of these tissue biomarkers in the daily practice of pathologists promises to better allocate patients with HCC with adequate treatments. In turn, this will likely boost the attitude of clinicians toward obtaining a pre-treatment biopsy. (J Liver Cancer 2022;22:14-22)

KCI등재

4Recent updates on the classification of hepatoblastoma according to the International Pediatric Liver Tumors Consensus

저자 : Se Un Jeong , Hyo Jeong Kang

발행기관 : 대한간암학회 간행물 : 대한간암학회지 22권 1호 발행 연도 : 2022 페이지 : pp. 23-29 (7 pages)

다운로드

(기관인증 필요)

초록보기

Hepatoblastoma is the most common pediatric liver malignancy and usually occurs within the first 3 years of life. In recent years, the overall incidence of hepatoblastoma has exhibited the greatest increase among all pediatric malignancies worldwide. The diagnosis of hepatoblastoma may be challenging due to the lack of a current consensus classification system. The International Pediatric Liver Tumors Consensus introduced guidelines and a consensus classification for the diagnosis of hepatoblastoma as either epithelial or mixed epithelial and mesenchymal and in the updated 5th edition of the World Health Organization Classification of Digestive System Tumors. (J Liver Cancer 2022;22:23-29)

KCI등재

5Diagnostic performance of serum exosomal miRNA-720 in hepatocellular carcinoma

저자 : Jeong Won Jang , Ji Min Kim , Hye Seon Kim , Jin Seoub Kim , Ji Won Han , Soon Kyu Lee , Heechul Nam , Pil Soo Sung , Si Hyun Bae , Jong Young Choi , Seung Kew Yoon

발행기관 : 대한간암학회 간행물 : 대한간암학회지 22권 1호 발행 연도 : 2022 페이지 : pp. 30-39 (10 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aim: Hepatocellular carcinoma (HCC) is associated with poor prognosis, largely due to late detection. Highly accurate biomarkers are urgently needed to detect early-stage HCC. Our study aims to explore the diagnostic performance of serum exosomal microRNA (miR)-720 in HCC.
Methods: Exosomal miRNA was measured via quantitative real-time PCR. A correlation analysis of exosomal miR-720 and tumor or clinico-demographic data of patients with HCC was performed. The receiver operating characteristic (ROC) curve was used to assess the diagnostic capacity of serum exosomal miR-720 for HCC, in comparison with α-fetoprotein (AFP) and prothrombin induced by vitamin K absence or antagonist-II (PIVKA-II).
Results: MiR-720 was chosen as a potential HCC marker via miR microarray based on significant differential expression between tumor and non-tumor samples. Serum exosomal miR-720 was significantly upregulated in patients with HCC (n=114) versus other liver diseases (control, n=30), with a higher area under the ROC curve (AUC, 0.931) than the other markers. Particularly, serum exosomal miR-720 showed superior performance in diagnosing small HCC (<5 cm; AUC, 0.930) compared with AFP (AUC, 0.802) or PIVKA-II (AUC, 0.718). Exosomal miR-720 levels showed marginal correlation with tumor size. The proportion of elevated miR-720 also increased with intrahepatic tumor stage progression. Unlike AFP or PIVKA-II showing a significant correlation with aminotransferase levels, the exosomal miR-720 level was not affected by aminotransferase levels.
Conclusions: Serum exosomal miR-720 is an excellent biomarker for the diagnosis of HCC, with better performance than AFP or PIVKA-II. Its diagnostic utility is maintained even in small HCC and is unaffected by aminotransferase levels. (J Liver Cancer 2022;22:30-39)

KCI등재

6The effects of immune checkpoint modulators on the clinical course of patients with resectable hepatocellular carcinoma

저자 : Jihyun An , Hyo Jeong Kang , Eunsil Yu , Han Chu Lee , Ju Hyun Shim

발행기관 : 대한간암학회 간행물 : 대한간암학회지 22권 1호 발행 연도 : 2022 페이지 : pp. 40-50 (11 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aim: Immune checkpoint proteins regulating T-cell mediated anti-tumor immunity have been reported to affect clinical outcomes in multiple malignancies. This study aimed to investigate the prognostic effect of histological expression of immune checkpoint proteins in patients with resected hepatocellular carcinoma (HCC).
Methods: A total of 221 patients with HCC who underwent curative resection were included. Expression of programmed-cell death ligand-1 (PD-L1) in tumor cells (tPD-L1) and tumor infiltrating mononuclear cells (TIMCs) (iPD-L1), programmed-cell death-1 in TIMCs (iPD-1), and cytotoxic T lymphocyte antigen-4 in TIMCs (iCTLA-4) were measured immunohistochemically.
Results: Histo-positivity for iCTLA-4, iPD-1, iPD-L1, and tPD-L1 was 32.1%, 42.5%, 35.3%, and 14.9%, respectively. Multivariate logistic analyses revealed that male sex and tumor >5 cm were variables related to iCTLA-4 positivity (odds ratio [OR], 0.46 and 1.94, respectively; P<0.05). Poor differentiation was related to PD-L1 expression in both tumor cells and TIMCs (OR, 2.88 and 3.46, respectively; P<0.05). Microvascular invasion was significantly associated only with iPD-L1 (OR, 2.24; P<0.05). In time-dependent outcome analyses, expression of immune checkpoint proteins in TIMCs (i.e., iCTLA-4, iPD-1, and iPD-L1) was significantly related to longer overall survival and non-cancer-related survival (all P<0.05), but not to time-to-recurrence or cancer-specific deaths. Concurrent activation of the PD-1:PD-L1 and CTLA-4 pathways predicted improved outcomes in terms of overall survival and non-cancer related survival (P=0.06 and P=0.03, respectively).
Conclusions: Immune checkpoint proteins upregulated in TIMCs in HCC tissues have individual and additive effects in prolonging the survival of patients, specifically in terms of survival not related to cancer recurrence. (J Liver Cancer 2022;22:40-50)

KCI등재

7Complete response to local therapy for advanced hepatocellular carcinoma with lung metastasis: a case report

저자 : Daeun Kim , Seiyeon Park , Won Sohn , Hyun Pyo Hong , Byung Ik Kim

발행기관 : 대한간암학회 간행물 : 대한간암학회지 22권 1호 발행 연도 : 2022 페이지 : pp. 51-56 (6 pages)

다운로드

(기관인증 필요)

초록보기

The concept of oligometastasis is widely accepted for various types of solid tumors; accordingly, better outcomes can be anticipated with aggressive local interventions. The treatment of advanced hepatocellular carcinoma (HCC) with extrahepatic metastasis is systemic therapy. However, treatment responses to systemic therapy are poor. Recently, a small number of metastatic cancers (oligometastasis) have been controlled by local therapy rather than systemic therapy. Our study reports a case of a 66-year-old male patient with advanced HCC with lung metastasis, which was treated with local therapy. There were less than four metastases in the lungs, which were treated with wedge resection, radiofrequency, and radiation therapy. He repeatedly underwent local therapy for lung oligometastasis and locoregional therapy for intrahepatic HCC rather than systemic therapy; control by local therapy was possible as his liver function was preserved with Child-Turcotte-Pugh class A. (J Liver Cancer 2022;22:51-56)

KCI등재

8A case report of advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy and sorafenib combination therapy followed by metastasectomy of lung and muscle metastases

저자 : Sang Yi Moon , Sang Young Han , Yang-hyun Baek

발행기관 : 대한간암학회 간행물 : 대한간암학회지 22권 1호 발행 연도 : 2022 페이지 : pp. 57-62 (6 pages)

다운로드

(기관인증 필요)

초록보기

Currently, various tyrosine kinase inhibitors and immune checkpoint inhibitors have been suggested in the treatment guidelines for advanced hepatocellular carcinoma (HCC). However, sorafenib was the only systemic drug approved 10 years ago. In 2010, a woman diagnosed with HCC rupture and multiple lung metastases visited our hospital. At the time of visiting our hospital, she had undergone transarterial chemoembolization at another hospital to control bleeding due to HCC rupture. We treated her with hepatic arterial infusion chemotherapy and sorafenib combination therapy to increase the control of intrahepatic tumors in consideration of the modest efficacy of sorafenib. The intrahepatic tumor was almost controlled. Metastasectomy was performed to control lung oligometastasis. Subsequently, additional muscle metastasis was confirmed, and metastasectomy was performed. Although this is a very rare case, it shows that a multidisciplinary approach can improve the prognosis of patients with HCC. (J Liver Cancer 2022;22:57-62)

KCI등재

9Sorafenib combined with radiation therapy for advanced hepatocellular carcinoma with portal and hepatic vein invasion extending to the inferior vena cava: a complete response case according to modified RECIST criteria

저자 : Yuri Cho , Bo Hyun Kim , Tae Hyun Kim , Young Hwan Koh , Joong-won Park

발행기관 : 대한간암학회 간행물 : 대한간암학회지 22권 1호 발행 연도 : 2022 페이지 : pp. 63-68 (6 pages)

다운로드

(기관인증 필요)

초록보기

The prognosis of patients with advanced hepatocellular carcinoma (HCC) with tumor thrombus extending to the inferior vena cava (IVC) is extremely poor. Herein, we present a rare case of advanced HCC that was treated with sorafenib and radiotherapy, leading to complete remission. This patient had a 9 cm infiltrative HCC occupying almost the entire left lobe with a tumor thrombus extending through the hepatic vein, IVC, and left portal vein. The patient received 400 mg sorafenib twice daily. One year after the start of sorafenib, intensity-modulated radiation therapy for viable HCC and tumor thrombus was performed with a dose of 5,500 cGy. Twenty-seven months after the starting date of sorafenib, there was no intratumoral arterial enhancement, which suggested a complete response according to the modified RECIST criteria. This case suggests that the combination of sorafenib and radiotherapy might provide clinical benefits in patients with advanced HCC with IVC tumor thrombus. (J Liver Cancer 2022;22:63-68)

KCI등재

10Concurrent transarterial radioembolization and combination atezolizumab/bevacizumab treatment of infiltrative hepatocellular carcinoma with portal vein tumor thrombosis: a case report

저자 : Min Kyung Park , Su Jong Yu

발행기관 : 대한간암학회 간행물 : 대한간암학회지 22권 1호 발행 연도 : 2022 페이지 : pp. 69-74 (6 pages)

다운로드

(기관인증 필요)

초록보기

Treatment options for advanced hepatocellular carcinoma (HCC) have been rapidly evolving. Herein, we describe a patient with advanced HCC and portal vein tumor thrombosis (PVTT) who responded decisively to a multidisciplinary approach. The patient had an ill-defined infiltrative HCC (diffuse subtype), with several intrahepatic metastasis and tumor invasion of left portal vein. Concurrent use of transarterial radioembolization (TARE) and systemic therapeutics (atezolizumab + bevacizumab) ultimately proved successful. There was marked reduction in tumor volume after TARE and an additional three cycles of atezolizumab plus bevacizumab. This concurrent treatment was well tolerated, without adverse events during immunotherapy. The impressive results achieved suggest that concurrent TARE and combination atezolizumab/bevacizumab is a promising treatment approach for advanced HCC with PVTT. (J Liver Cancer 2022;22:69-74)

12
권호별 보기

내가 찾은 최근 검색어

최근 열람 자료

맞춤 논문

보관함

내 보관함
공유한 보관함

1:1문의

닫기